These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35248829)

  • 1. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.
    Silic-Benussi M; Sharova E; Ciccarese F; Cavallari I; Raimondi V; Urso L; Corradin A; Kotler H; Scattolin G; Buldini B; Francescato S; Basso G; Minuzzo SA; Indraccolo S; D'Agostino DM; Ciminale V
    Redox Biol; 2022 May; 51():102268. PubMed ID: 35248829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus.
    Silic-Benussi M; Sharova E; Corradin A; Urso L; Raimondi V; Cavallari I; Buldini B; Francescato S; Minuzzo SA; D'Agostino DM; Ciminale V
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis.
    Silic-Benussi M; Scattolin G; Cavallari I; Minuzzo S; Del Bianco P; Francescato S; Basso G; Indraccolo S; D'Agostino DM; Ciminale V
    Cell Death Dis; 2018 Aug; 9(8):822. PubMed ID: 30069011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism.
    Dando I; Pacchiana R; Pozza ED; Cataldo I; Bruno S; Conti P; Cordani M; Grimaldi A; Butera G; Caraglia M; Scarpa A; Palmieri M; Donadelli M
    Free Radic Biol Med; 2017 Dec; 113():176-189. PubMed ID: 28962872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
    Carroll WL; Aifantis I; Raetz E
    Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
    Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
    Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
    Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
    Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
    Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
    Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
    Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
    Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.
    Zhang C; Ryu YK; Chen TZ; Hall CP; Webster DR; Kang MH
    Leuk Res; 2012 Mar; 36(3):342-9. PubMed ID: 22137317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
    Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
    Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
    Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
    Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
    Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
    Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
    [No Abstract]   [Full Text] [Related]  

  • 17. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
    Baraz R; Cisterne A; Saunders PO; Hewson J; Thien M; Weiss J; Basnett J; Bradstock KF; Bendall LJ
    PLoS One; 2014; 9(7):e102494. PubMed ID: 25014496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
    Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
    Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
    Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
    Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
    Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
    Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.